Anlagebedingter Haarausfall und aktuelle Therapiekonzepte

Zusammenfassung

Die androgenetische oder anlagebedingte Alopezie ist die häufigste Form des Haarausfalls. Hier hat sich ein integratives Behandlungskonzept bewährt. Neben den zwei Hauptfaktoren genetische Prädisposition und Androgene, die die hormonelle Therapie in den Mittelpunkt stellen, werden auch verschiedene Nebenfaktoren wie Seborrhö und Kolonisation, Vaskularisierung und Gefäßversorgung sowie Mikroinflammation und Fibrosierung als therapeutische Ansatzpunkte genutzt. So unterstützen antientzündliche, antifibrotische und antimikrobiell wirkende Substanzen den Erfolg der hormonellen Therapie und erhöhen den Therapieerfolg und die Zufriedenheit der meist recht anspruchsvollen Patienten. Die vorliegende Arbeit gibt einen Überblick über die verschiedenen Pathomechanismen des anlagebedingten Haarausfalls und die hierauf basierenden therapeutischen Ansatzpunkte.

Abstract

Androgenetic alopecia or genetic hair loss is the most common form of hair loss. An integrative treatment concept has proved to be a reliable therapeutic strategy. Therefore, treatment strategies not only focus on the two main factors “genetic predisposition” and “androgens” but also include other adjacent factors, such as seborrhoea and colonization, vascularization and vascular supply, as well as microinflammation and fibrosis, which also require therapeutic measures. Antiinflammatory, antifibrotic, and antimicrobial substances support the success of the hormonal therapy, as well as satisfying the needs of demanding patients. This article presents an overview of the different pathomechanisms of androgenetic alopecia and subsequent therapeutical strategies.

Literatur

• 1 Hamilton J B. Patterned hair loss in man: types and incidence.  Ann N Y Acad Sci. 1951;  53 708-728
• 2 Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.  Br J Dermatol. 1977;  97 247-254
• 3 Olsen E A. The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women.  J Am Acad Dermatol. 1999;  40 106-109
• 4 Sawaya M, Price V. Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.  J Invest Dermatol. 1997;  109 296-300
• 5 Orfanos C E, Garbe C (Hrsg). Häufige Haarkrankheiten. In: Therapie der Hautkrankheiten. Springer Verlag 2002: 1396-1422
• 6 Kozlowska U, Blume-Peytavi U, Kodelja V, Sommer C, Goerdt S, Jablonska S, Orfanos C E. Vascular endothelial growth factor induced by proinflammatory cytokines (IL-1α, β) in cells of the human pilosebaceous unit.  Dermatology. 1998;  196 89-92
• 7 Lattanad A, Johnson W C. Male pattern alopecia. A histopathologic and histochemical study.  J Cutaneous Pathology. 1975;  2 58-70
• 8 Arck P C, Handjiski B, Hagen B, Hagen E, Joachim R, Klapp B F, Paus R. Indications for a „brain-hair follicle axis (BHA)“: inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P.  FASEB J. 2001;  15 2536-2538
• 9 Kozlowska U, Blume-Peytavi U, Kodelja V, Sommer C, Majewski S, Jablonska S, Goerdt S, Orfanos C E. Vascular endothelial growth factor expression in various compartments of the human hair follicle.  Arch Derm Res. 1998;  290 661-668
• 10 Lachgar S, Monkadiri H, Jonca F, Charveron M, Bouhaddioui N, Gall Y, Bonafe J L, Plouet J. Vascular endothelial factor is an autocrine growth factor for hair dermal papilla cells.  J Invest Dermatol. 1996;  106 17-23
• 11 Wolf R, Schönfelder G, Paul M, Blume-Peytavi U. Nitric oxide in the human hair follicle: Constitutive and dihydrotestosterone induced nitric oxide synthase expression and NO production in dermal papilla cells, .  J Mol Med. 2002;  in press
• 12 Orfanos C E, Vogels L. Local therapy of androgenetic alopecia with 17 alpha-estradiol. A controlled randomized double-blind study.  Dermatologica. 1980;  161 124-132
• 13 Oh H S, Smart R C. An estrogen receptor pathway regulates the telogen-anagen hair-follicle transition and influences epidermal cell proliferation.  N Proc Acad Sci. 1996;  93 12 525-12 530
• 14 Smart R C, Oh H S. On the effect of estrogen receptor agonists and antagonists on the mouse hair follicle cycle.  J Invest Dermatol. 1998;  111 175
• 15 Kaufman K D, Olsen E A, Whiting D. et al . Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.  J Am Acad Dermatol. 1998;  39 578-589
• 16 Price V H, Roberts J L, Hordinsky M. et al . Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.  J Am Acad Dermatol. 2000;  43 768-776
• 17 Lachgar S, Charveron M, Gall Y, Bonafe J L. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells.  Br J Dermatol. 1998;  38 407-411
• 18 Connors T J, Cooke T E, De Launey W E. et al . Australian trial of topical minoxidil and placebo in early male pattern baldness.  Australas J Dermatol. 1990;  31 17-25
• 19 de Groot A C, Nater J P, Herxheimer A. Minoxidil for male-pattern baldness.  Lancet. 1987;  2 563
• 20 de Groot A C, Nater J P, Herxheimer A. Minoxidil: hope for the bald?.  Lancet. 1987;  1 1019-1022
• 21 Koperski J A, Orenberg E K, Wilkinson D I. Topical minoxidil therapy for androgenetic alopecia. A 30-month study.  Arch Dermatol. 1987;  123 1483-1487
• 22 Data on file (data on file, Vichy-Cosmétique Active Deutschland/L'Oréal). 
• 23 Herel H, Gollnick H, Matthies C, Baumann I, Orfanos LE. Low dosage retinol and L-cystine combination improve alopecia of the diffuse type following long-term oral administration.  Hautarzt. 1989;  40 (8) 490-495